🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

74+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 14 of 74 recruiting trials for “chronic-neutrophilic-leukemia”

Phase 3RecruitingNCT04269902 ↗

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

👨‍⚕️ Deborah M Stephens, SWOG Cancer Research Network📍 627 sites📅 Started Mar 2021View details ↗
Phase 1RecruitingNCT04223765 ↗

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

👨‍⚕️ Natalie Grover, MD, UNC Lineberger Comprehensive Cancer Center📍 1 site📅 Started Nov 2020View details ↗
Phase 1RecruitingNCT04545762 ↗

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

👨‍⚕️ Carrie Ho, MD, University of California, San Francisco📍 1 site📅 Started Sep 2020View details ↗
Phase 2RecruitingNCT04169737 ↗

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

👨‍⚕️ William G Wierda, M.D. Anderson Cancer Center📍 1 site📅 Started Jul 2020View details ↗
Phase 1RecruitingNCT04215809 ↗

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

👨‍⚕️ Yifan Zhai, MD, PhD, Ascentage Pharma Group Inc.📍 9 sites📅 Started Mar 2020View details ↗
Phase 2RecruitingNCT03986034 ↗

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

👨‍⚕️ Christine E Gruessner, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Jun 2019View details ↗
Phase 1RecruitingNCT03666000 ↗

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

👨‍⚕️ John Byon, MD, PhD, Imugene Limited📍 23 sites📅 Started Mar 2019View details ↗
RecruitingNCT03501576 ↗

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

👨‍⚕️ Andres Chang, MD, PhD, Emory University📍 2 sites📅 Started Apr 2018View details ↗
RecruitingNCT03342144 ↗

Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

👨‍⚕️ ABBVIE INC., AbbVie📍 70 sites📅 Started Dec 2017View details ↗
RecruitingNCT03375619 ↗

Long-term Follow-up Study of Patients Receiving CAR-T Cells

👨‍⚕️ Nirav Shah, Medical College of Wisconsin📍 1 site📅 Started Dec 2017View details ↗
Phase 2RecruitingNCT02966756 ↗

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

👨‍⚕️ ABBVIE INC., AbbVie📍 31 sites📅 Started Oct 2017View details ↗
RecruitingNCT03197259 ↗

Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study

👨‍⚕️ Fatih Demirkan, Prof, Dokuz Eylum Medical Faculty📍 1 site📅 Started Jan 2017View details ↗
Phase 3RecruitingNCT01804686 ↗

A Long-term Extension Study of PCI-32765 (Ibrutinib)

👨‍⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 174 sites📅 Started Sep 2013View details ↗
RecruitingNCT04028531 ↗

Understanding Chronic Lymphocytic Leukemia

👨‍⚕️ Jennifer Brown, MD,PhD, Dana-Farber Cancer Institute📍 1 site📅 Started Sep 1999View details ↗
← PreviousPage 4 of 4

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →